Zoledronic acid combined with androgen-deprivation therapy may prolong time to castration-resistant prostate cancer in hormone-naïve metastatic prostate cancer patients – A propensity scoring approach
Objective: To clarify the oncological benefit of zoledronic acid for hormone-naïve metastatic prostate cancer, patient outcome of androgen deprivation therapy with zoledronic acid (ADT + Z) and androgen deprivation therapy alone (ADT) was compared. Methods: Fifty-two patients with pathologically con...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2016-01-01
|
| Series: | Asian Journal of Urology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2214388215001149 |
| _version_ | 1818584819339100160 |
|---|---|
| author | Kazuhiro Nagao Hideyasu Matsuyama Masahiro Nozawa Isao Hara Tsukasa Nishioka Takahiro Komura Atsunobu Esa Shigeya Uejima Masaaki Imanishi Yasunari Uekado Takatoshi Ogawa Hiroshi Kajikawa Hirotsugu Uemura |
| author_facet | Kazuhiro Nagao Hideyasu Matsuyama Masahiro Nozawa Isao Hara Tsukasa Nishioka Takahiro Komura Atsunobu Esa Shigeya Uejima Masaaki Imanishi Yasunari Uekado Takatoshi Ogawa Hiroshi Kajikawa Hirotsugu Uemura |
| author_sort | Kazuhiro Nagao |
| collection | DOAJ |
| description | Objective: To clarify the oncological benefit of zoledronic acid for hormone-naïve metastatic prostate cancer, patient outcome of androgen deprivation therapy with zoledronic acid (ADT + Z) and androgen deprivation therapy alone (ADT) was compared.
Methods: Fifty-two patients with pathologically confirmed metastatic prostate cancer were prospectively enrolled and treated with combined androgen blockade (goserelin and bicalutamide) with zoledronic acid (4 mg every 4 weeks for 24 months). A propensity score-match with logistic regression analysis was applied to select 50 pair-matched cohorts (both from ADT + Z and from historical control cohorts who had undergone ADT alone), and patient outcomes were compared.
Results: Patients with ADT + Z had significantly longer time to progression (TTP) than those with ADT (median TTP; 24.2 vs. 14.0 months, p = 0.0092), while no significant difference of overall survival between two groups (p = 0.1502). Multivariate analysis for biochemical recurrence revealed treatment with ADT was the sole independent prognostic factor (HR: 1.724, 95% CI: 1.06–2.86, p = 0.0297).
Conclusion: Combination of zoledronic acid with ADT may prolong time to castration resistant prostate cancer. |
| first_indexed | 2024-12-16T08:27:14Z |
| format | Article |
| id | doaj.art-ca62a73c993f4192813c7f49c66fa070 |
| institution | Directory Open Access Journal |
| issn | 2214-3882 |
| language | English |
| last_indexed | 2024-12-16T08:27:14Z |
| publishDate | 2016-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Asian Journal of Urology |
| spelling | doaj.art-ca62a73c993f4192813c7f49c66fa0702022-12-21T22:37:58ZengElsevierAsian Journal of Urology2214-38822016-01-0131333810.1016/j.ajur.2015.10.003Zoledronic acid combined with androgen-deprivation therapy may prolong time to castration-resistant prostate cancer in hormone-naïve metastatic prostate cancer patients – A propensity scoring approachKazuhiro Nagao0Hideyasu Matsuyama1Masahiro Nozawa2Isao Hara3Tsukasa Nishioka4Takahiro Komura5Atsunobu Esa6Shigeya Uejima7Masaaki Imanishi8Yasunari Uekado9Takatoshi Ogawa10Hiroshi Kajikawa11Hirotsugu Uemura12Department of Urology, Graduate School of Medicine, Yamaguchi University, JapanDepartment of Urology, Graduate School of Medicine, Yamaguchi University, JapanDepartment of Urology, Kinki University Faculty of Medicine, JapanDepartment of Urology, Wakayama Medical University School of Medicine, JapanDepartment of Urology, Sakai Hospital, Kinki University Faculty of Medicine, JapanDepartment of Urology, Naga Hospital, JapanDepartment of Urology, NTT Osaka Hospital, JapanDepartment of Urology, National Hospital Organization Osaka Minami Medical Center, JapanDepartment of Urology, Tondabayashi Hospital, JapanDepartment of Urology, Wakayama Rosai Hospital, JapanDepartment of Urology, Kainan Municipal Hospital, JapanDepartment of Urology, Izumiotsu Municipal Hospital, JapanDepartment of Urology, Kinki University Faculty of Medicine, JapanObjective: To clarify the oncological benefit of zoledronic acid for hormone-naïve metastatic prostate cancer, patient outcome of androgen deprivation therapy with zoledronic acid (ADT + Z) and androgen deprivation therapy alone (ADT) was compared. Methods: Fifty-two patients with pathologically confirmed metastatic prostate cancer were prospectively enrolled and treated with combined androgen blockade (goserelin and bicalutamide) with zoledronic acid (4 mg every 4 weeks for 24 months). A propensity score-match with logistic regression analysis was applied to select 50 pair-matched cohorts (both from ADT + Z and from historical control cohorts who had undergone ADT alone), and patient outcomes were compared. Results: Patients with ADT + Z had significantly longer time to progression (TTP) than those with ADT (median TTP; 24.2 vs. 14.0 months, p = 0.0092), while no significant difference of overall survival between two groups (p = 0.1502). Multivariate analysis for biochemical recurrence revealed treatment with ADT was the sole independent prognostic factor (HR: 1.724, 95% CI: 1.06–2.86, p = 0.0297). Conclusion: Combination of zoledronic acid with ADT may prolong time to castration resistant prostate cancer.http://www.sciencedirect.com/science/article/pii/S2214388215001149Zoledronic acidHormone-naïve prostate cancerBiochemical recurrencePropensity score-match analysis |
| spellingShingle | Kazuhiro Nagao Hideyasu Matsuyama Masahiro Nozawa Isao Hara Tsukasa Nishioka Takahiro Komura Atsunobu Esa Shigeya Uejima Masaaki Imanishi Yasunari Uekado Takatoshi Ogawa Hiroshi Kajikawa Hirotsugu Uemura Zoledronic acid combined with androgen-deprivation therapy may prolong time to castration-resistant prostate cancer in hormone-naïve metastatic prostate cancer patients – A propensity scoring approach Asian Journal of Urology Zoledronic acid Hormone-naïve prostate cancer Biochemical recurrence Propensity score-match analysis |
| title | Zoledronic acid combined with androgen-deprivation therapy may prolong time to castration-resistant prostate cancer in hormone-naïve metastatic prostate cancer patients – A propensity scoring approach |
| title_full | Zoledronic acid combined with androgen-deprivation therapy may prolong time to castration-resistant prostate cancer in hormone-naïve metastatic prostate cancer patients – A propensity scoring approach |
| title_fullStr | Zoledronic acid combined with androgen-deprivation therapy may prolong time to castration-resistant prostate cancer in hormone-naïve metastatic prostate cancer patients – A propensity scoring approach |
| title_full_unstemmed | Zoledronic acid combined with androgen-deprivation therapy may prolong time to castration-resistant prostate cancer in hormone-naïve metastatic prostate cancer patients – A propensity scoring approach |
| title_short | Zoledronic acid combined with androgen-deprivation therapy may prolong time to castration-resistant prostate cancer in hormone-naïve metastatic prostate cancer patients – A propensity scoring approach |
| title_sort | zoledronic acid combined with androgen deprivation therapy may prolong time to castration resistant prostate cancer in hormone naive metastatic prostate cancer patients a propensity scoring approach |
| topic | Zoledronic acid Hormone-naïve prostate cancer Biochemical recurrence Propensity score-match analysis |
| url | http://www.sciencedirect.com/science/article/pii/S2214388215001149 |
| work_keys_str_mv | AT kazuhironagao zoledronicacidcombinedwithandrogendeprivationtherapymayprolongtimetocastrationresistantprostatecancerinhormonenaivemetastaticprostatecancerpatientsapropensityscoringapproach AT hideyasumatsuyama zoledronicacidcombinedwithandrogendeprivationtherapymayprolongtimetocastrationresistantprostatecancerinhormonenaivemetastaticprostatecancerpatientsapropensityscoringapproach AT masahironozawa zoledronicacidcombinedwithandrogendeprivationtherapymayprolongtimetocastrationresistantprostatecancerinhormonenaivemetastaticprostatecancerpatientsapropensityscoringapproach AT isaohara zoledronicacidcombinedwithandrogendeprivationtherapymayprolongtimetocastrationresistantprostatecancerinhormonenaivemetastaticprostatecancerpatientsapropensityscoringapproach AT tsukasanishioka zoledronicacidcombinedwithandrogendeprivationtherapymayprolongtimetocastrationresistantprostatecancerinhormonenaivemetastaticprostatecancerpatientsapropensityscoringapproach AT takahirokomura zoledronicacidcombinedwithandrogendeprivationtherapymayprolongtimetocastrationresistantprostatecancerinhormonenaivemetastaticprostatecancerpatientsapropensityscoringapproach AT atsunobuesa zoledronicacidcombinedwithandrogendeprivationtherapymayprolongtimetocastrationresistantprostatecancerinhormonenaivemetastaticprostatecancerpatientsapropensityscoringapproach AT shigeyauejima zoledronicacidcombinedwithandrogendeprivationtherapymayprolongtimetocastrationresistantprostatecancerinhormonenaivemetastaticprostatecancerpatientsapropensityscoringapproach AT masaakiimanishi zoledronicacidcombinedwithandrogendeprivationtherapymayprolongtimetocastrationresistantprostatecancerinhormonenaivemetastaticprostatecancerpatientsapropensityscoringapproach AT yasunariuekado zoledronicacidcombinedwithandrogendeprivationtherapymayprolongtimetocastrationresistantprostatecancerinhormonenaivemetastaticprostatecancerpatientsapropensityscoringapproach AT takatoshiogawa zoledronicacidcombinedwithandrogendeprivationtherapymayprolongtimetocastrationresistantprostatecancerinhormonenaivemetastaticprostatecancerpatientsapropensityscoringapproach AT hiroshikajikawa zoledronicacidcombinedwithandrogendeprivationtherapymayprolongtimetocastrationresistantprostatecancerinhormonenaivemetastaticprostatecancerpatientsapropensityscoringapproach AT hirotsuguuemura zoledronicacidcombinedwithandrogendeprivationtherapymayprolongtimetocastrationresistantprostatecancerinhormonenaivemetastaticprostatecancerpatientsapropensityscoringapproach |